pharma · Moderate to severe systemic lupus erythematosus · Lupus Erythematosus, Systemic
Viatris Pharmaceuticals Co
Viatris Pharmaceuticals Co.,
Viatris Pharmaceuticals Co clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- FR
- Employees
- 4
- Programs
- 8
- Drugs
- 23
- Patents
- 0
Viatris Pharmaceuticals Co projects
8 ClinicalTrials.gov programs sponsored by Viatris Pharmaceuticals Co.
Viatris Pharmaceuticals Co has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Cenerimod
Viatris Pharmaceuticals Co.,
Lupus Erythematosus, Systemic
2 trials -
Cenerimod 4 mg
Viatris Pharmaceuticals Co.,
Systemic lupus erythematosus
1 trial -
Cenerimod 4 mg, Cenerimod matching placebo
Viatris Pharmaceuticals Co.,
Moderate to severe systemic lupus erythematosus
1 trial -
Cenerimod matching placebo, Cenerimod 4 mg
Viatris Pharmaceuticals Co.,
Moderate to severe systemic lupus erythematosus
1 trial -
ID-076A301
Viatris Pharmaceuticals Co.,
Acute myocardial infarction (AMI)
1 trial -
Selatogrel
Viatris Pharmaceuticals Co.,
Acute Myocardial Infarction
1 trial -
Selatogrel
Viatris Pharmaceuticals Co.,
Stable Coronary Artery Disease
1 trial -
ID-064-108
Viatris Pharmaceuticals Co.,
Not applicable - healthy volunteer trial
1 trial
Frequently asked questions
How many clinical projects does Viatris Pharmaceuticals Co have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.